Saphnelo
Chemical Name | anifrolumab-fnia |
Dosage Form | Injection (intravenous; 150 mg/mL) |
Drug Class | Receptor antagonists |
System | Immune |
Company | AstraZeneca |
Approval Year | 2021 |
Indication
- For the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy